IVIG Market Analysis: Rising Demand to Drive USD 21.06 Billion Valuation by 2030
The global Intravenous Immunoglobulin Market was valued at USD 11.17 billion in 2021 and is projected to grow from USD XX billion in 2022 to USD 21.06 billion by 2030, at a CAGR of 7.3% during the forecast period (2022–2030).
Market Catalysts for Expansion
The growth of the Intravenous Immunoglobulin (IVIG) Market is driven by the rising prevalence of immunodeficiency disorders, increased awareness of IVIG therapy, and technological advancements in plasma-derived products. The growing geriatric population, which is more susceptible to immune system disorders, along with an increasing number of FDA approvals for IVIG therapies, further fuels market expansion. Additionally, the demand for immunoglobulin treatments for neurological diseases is contributing to market growth.
Market Segment Breakdown
By Application:
Hypogammaglobulinemia
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Immunodeficiency Diseases
Congenital AIDS
Chronic Lymphocytic Leukemia
Myasthenia Gravis
Multifocal Motor Neuropathy
Immune Thrombocytopenic Purpura (ITP)
Kawasaki Disease
Guillain-Barré Syndrome
By Distribution Channel:
Hospital Pharmacy
Specialty Pharmacy
Top Performing Companies
Baxalta Incorporated
Biotest AG
China Biologic Products Inc.
CSL Behring LLC
Grifols S.A.
Kedrion S.p.A.
LFB Biomedicaments S.A.
Octapharma AG
Sanquin Plasma Products B.V.
Bharat Serums and Vaccines Limited
Download Free Sample Report with Complimentary Analyst Consultation : https://straitsresearch.com/report/intravenous-immunoglobulin-market/request-sample
Emerging Prospects
The market is expected to witness further growth with ongoing research into novel immunoglobulin therapies and increasing government initiatives to support plasma collection and immunoglobulin production. Advances in recombinant immunoglobulins and subcutaneous alternatives also provide promising opportunities.
Industry Movements
Several key industry movements are shaping the IVIG Market, including strategic acquisitions, collaborations, and expansion initiatives by major players. Increased investment in R&D, particularly for treating neurological and autoimmune disorders, is enhancing the therapeutic landscape. Regulatory advancements are also facilitating quicker approval of IVIG products.
Geographic Analysis
North America holds the largest market share due to well-established healthcare infrastructure and strong government support for immunoglobulin therapies. Europe follows closely with increasing awareness and adoption of plasma-derived products. The Asia-Pacific region is expected to witness the highest growth rate due to a rising prevalence of immunodeficiency diseases and expanding healthcare expenditure in countries such as China, India, and Japan.
Data Insights
The market's steady growth is supported by an increase in plasma collection centers, technological innovations, and improvements in cold chain logistics for the safe transportation of IVIG products. With the growing demand for personalized medicine, new formulations of IVIG therapy are likely to gain traction in the coming years.
Contact Us
Email: sales@straitsresearch.com
Address: 825 3rd Avenue, New York, NY, USA, 10022
Phone: +1 646 905 0080 (US), +91 8087085354 (India), +44 203 695 0070 (UK)
